Belite Bio Inc ADR
| NASDAQ: BLTE | Healthcare / Biotechnology / USA |
| 27.01 | +0.1300 | +0.48% | Vol 17.10K | 1Y Perf - |
| Mar 24th, 2023 15:59 DELAYED |
| BID | 25.00 | ASK | 31.00 | ||
| Open | 27.30 | Previous Close | 26.88 | ||
| Pre-Market | - | After-Market | 27.00 | ||
| - - | -0.01 -0.04% |
| Target Price | 57.50 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 112.88 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 50.72 | Earnings Rating | — | |
| Market Cap | 671.66M | Earnings Date | 5th May 2023 | |
| Alpha | 0.43 | Standard Deviation | 0.45 | |
| Beta | -7.52 |
Today's Price Range 27.0028.00 | 52W Range 8.8044.70 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -5.13% | ||
| 1 Month | -15.17% | ||
| 3 Months | -12.56% | ||
| 6 Months | -27.00% | ||
| 1 Year | - | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -16.94 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -16.46 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -16.94 | |||
Return on invested Capital Q | - | |||
Return on invested Capital Y | - | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -68.90 | ||||
| 15.03 | ||||
| - | ||||
| - | ||||
| -98.50 | ||||
| -0.30 | ||||
| 15.03 | ||||
| 2.00 | ||||
| 745.77M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| 10.70 | ||||
| - | ||||
| - | ||||
| - | ||||
| Leverage Ratio | 1.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 5th May 2023 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 17.10K |
| Shares Outstanding | 24.87K |
| Shares Float | 24.10M |
| Trades Count | 459 |
| Dollar Volume | 468.68K |
| Avg. Volume | 18.48K |
| Avg. Weekly Volume | 30.47K |
| Avg. Monthly Volume | 13.81K |
| Avg. Quarterly Volume | 11.16K |
Belite Bio Inc ADR (NASDAQ: BLTE) stock closed at 27.01 per share at the end of the most recent trading day (a 0.48% change compared to the prior day closing price) with a volume of 17.10K shares and market capitalization of 671.66M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 12 people. Belite Bio Inc ADR CEO is .
The one-year performance of Belite Bio Inc ADR stock is %, while year-to-date (YTD) performance is -10.4%. BLTE stock has a five-year performance of %. Its 52-week range is between 8.8 and 44.7, which gives BLTE stock a 52-week price range ratio of 50.72%
Belite Bio Inc ADR currently has a PE ratio of -68.90, a price-to-book (PB) ratio of 15.03, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -16.46%, a ROC of -16.94% and a ROE of -16.94%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Belite Bio Inc ADR, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Belite Bio Inc ADR’s next earnings report date is 05th May 2023.
The consensus rating of Wall Street analysts for Belite Bio Inc ADR is Strong Buy (1), with a target price of $57.5, which is +112.88% compared to the current price. The earnings rating for Belite Bio Inc ADR stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Belite Bio Inc ADR has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Belite Bio Inc ADR has a Sell technical analysis rating based on Technical Indicators (ADX : 33.07, ATR14 : 1.71, CCI20 : -125.06, Chaikin Money Flow : -0.50, MACD : -1.21, Money Flow Index : 40.93, ROC : -16.89, RSI : 36.97, STOCH (14,3) : 18.36, STOCH RSI : 0.50, UO : 27.79, Williams %R : -81.64), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Belite Bio Inc ADR in the last 12-months were:
Belite Bio Inc ADR
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
CEO:
Telephone: +1 858 246-6240
Address: 5820 Oberlin Drive, San Diego 92121, CA, US
Number of employees: 12
